5.35
price up icon8.08%   0.40
 
loading
Atyr Pharma Inc stock is traded at $5.35, with a volume of 6.03M. It is up +8.08% in the last 24 hours and up +2.10% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$4.95
Open:
$5.11
24h Volume:
6.03M
Relative Volume:
1.59
Market Cap:
$524.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.18%
1M Performance:
+2.10%
6M Performance:
+23.84%
1Y Performance:
+186.10%
1-Day Range:
Value
$5.05
$5.455
1-Week Range:
Value
$4.58
$5.455
52-Week Range:
Value
$1.67
$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
Name
Atyr Pharma Inc
Name
Phone
(858) 731-8389
Name
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ATYR's Discussions on Twitter

Compare ATYR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATYR
Atyr Pharma Inc
5.35 481.11M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-18-25 Initiated Leerink Partners Outperform
Jan-06-25 Initiated Cantor Fitzgerald Overweight
Oct-04-24 Initiated Wells Fargo Overweight
Sep-05-24 Initiated Jefferies Buy
Jul-05-23 Downgrade Oppenheimer Outperform → Perform
Oct-12-21 Initiated RBC Capital Mkts Outperform
Sep-21-21 Initiated Piper Sandler Overweight
May-10-21 Initiated Laidlaw Buy
Aug-17-20 Upgrade H.C. Wainwright Neutral → Buy
Mar-04-20 Initiated ROTH Capital Buy
Mar-02-20 Initiated Oppenheimer Outperform
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Sep-07-17 Initiated Piper Jaffray Overweight
Dec-13-16 Downgrade JP Morgan Overweight → Neutral
Dec-16-15 Initiated Citigroup Neutral
Jun-01-15 Initiated Citigroup Buy
Jun-01-15 Initiated JP Morgan Overweight
View All

Atyr Pharma Inc Stock (ATYR) Latest News

pulisher
Aug 20, 2025

What institutional flow reveals about aTyr Pharma Inc.Long Setup & Weekly High Return Stock Opportunities - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

How to track smart money flows in aTyr Pharma Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Is it too late to sell aTyr Pharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

How to use a screener to detect aTyr Pharma Inc. breakoutsQuarterly Earnings Report & Technical Entry and Exit Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Moving Average Crossover Confirms Uptrend in aTyr Pharma Inc.2025 Bull vs Bear & Stepwise Trade Execution Plans - beatles.ru

Aug 20, 2025
pulisher
Aug 20, 2025

aTyr Pharma Inc.’s volatility index tracking explainedJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - Yahoo Finance

Aug 20, 2025
pulisher
Aug 20, 2025

Live market analysis of aTyr Pharma Inc.Gold Moves & Free Safe Capital Growth Stock Tips - Newser

Aug 20, 2025
pulisher
Aug 19, 2025

Is aTyr Pharma Inc. stock bottoming outBreakout Watch & Free Growth Oriented Trading Recommendations - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Analyzing drawdowns of aTyr Pharma Inc. with statistical tools2025 Valuation Update & Real-Time Stock Movement Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What makes aTyr Pharma Inc. stock price move sharplyNew Guidance & High Return Stock Watch Alerts - beatles.ru

Aug 19, 2025
pulisher
Aug 19, 2025

Technical analysis overview for aTyr Pharma Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Developing predictive dashboards with aTyr Pharma Inc. dataEarnings Risk Summary & Real-Time Price Movement Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

High Growth US Tech Stocks To Watch In August 2025 - Yahoo Finance

Aug 19, 2025
pulisher
Aug 19, 2025

RSI Crosses Above 30 for aTyr Pharma Inc. — Reversal in SightTrade Analysis Summary & Daily Stock Trend Reports - beatles.ru

Aug 19, 2025
pulisher
Aug 19, 2025

Regression analysis insights on aTyr Pharma Inc. performanceEarnings Risk Report & AI Driven Stock Reports - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome (NASDAQ:ATYR) - Seeking Alpha

Aug 19, 2025
pulisher
Aug 19, 2025

Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Activity Summary & Weekly High Return Stock Forecasts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Risk adjusted return profile for aTyr Pharma Inc. analyzed2025 Key Lessons & Breakout Confirmation Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Heatmap analysis for aTyr Pharma Inc. and competitorsWeekly Trade Review & Verified Short-Term Plans - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Is aTyr Pharma Inc. a play on infrastructure spendingDividend Hike & Daily Growth Stock Tips - newsimpact.co.kr

Aug 18, 2025
pulisher
Aug 18, 2025

Applying Elliott Wave Theory to aTyr Pharma Inc.Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

How to escape a deep drawdown in aTyr Pharma Inc.2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Can machine learning forecast aTyr Pharma Inc. recoveryIndex Update & AI Forecasted Entry and Exit Points - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Is aTyr Pharma Inc. exposed to currency risksTrend Reversal & AI Enhanced Trade Execution Alerts - thegnnews.com

Aug 16, 2025
pulisher
Aug 16, 2025

XTX Topco Ltd Has $59,000 Stock Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World

Aug 16, 2025
pulisher
Aug 16, 2025

Trendlines Suggest aTyr Pharma Inc. May Bottom Out SoonTechnical Breakout Signal Plan Strategy - beatles.ru

Aug 16, 2025
pulisher
Aug 15, 2025

Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study - TipRanks

Aug 15, 2025
pulisher
Aug 14, 2025

Custom Dashboard Highlights aTyr Pharma Inc. Price MomentumEarnings Miss & Free Growth Oriented Trading Recommendations - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

aTyr Pharma Inc. Shows Support at Fibonacci LevelJuly 2025 EndofMonth & Fast Moving Market Watchlists - newsyoung.net

Aug 14, 2025
pulisher
Aug 14, 2025

Published on: 2025-08-14 00:58:46 - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Cullinan Management (CGEM) and aTyr Pharma (ATYR) - The Globe and Mail

Aug 13, 2025
pulisher
Aug 12, 2025

Will aTyr Pharma Inc. Bounce From 52 Week LowPotential Breakout Stock List Published This Week - sundaytimes.kr

Aug 12, 2025
pulisher
Aug 12, 2025

ATYR.O Plummets 7.8%: A Deep Dive into the Unusual Intraday Move - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

aTyr Pharma Inc. Outperforms Peers on Volume MetricsSwing Setup With Technical Confirmation Explained - 선데이타임즈

Aug 12, 2025
pulisher
Aug 12, 2025

Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2025
pulisher
Aug 09, 2025

Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it

Aug 09, 2025
pulisher
Aug 08, 2025

Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com

Aug 08, 2025
pulisher
Aug 08, 2025

Connect Biopharma Holdings Limited shares rise 1.93% intraday after aTyr Pharma announced Phase 3 EFZO-FIT™ study completion. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

aTyr Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 08, 2025

3 Innovation Stocks With Parabolic Upside Potential - AOL.com

Aug 08, 2025
pulisher
Aug 08, 2025

Atyr Pharma: Q2 Earnings Snapshot - Connecticut Post

Aug 08, 2025
pulisher
Aug 08, 2025

aTyr Pharma Reports Q2 2025 Financial Results - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

ATYR Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Aug 07, 2025

Atyr Pharma Inc Stock (ATYR) Financials Data

There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Atyr Pharma Inc Stock (ATYR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Broadfoot Jill Marie
Chief Financial Officer
Feb 04 '25
Sale
3.78
1,254
4,740
31,763
DENYES NANCY
General Counsel
Feb 04 '25
Sale
3.78
899
3,398
26,555
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):